

### **Anti-PIM1 Rabbit Monoclonal Antibody**

Catalog # ABO13388

### **Specification**

## **Anti-PIM1 Rabbit Monoclonal Antibody - Product Information**

Application WB, IHC, IF, ICC

Primary Accession
Host
Rabbit
Isotype
Reactivity
Clonality
Format
Rabbit IgG
Human, Mouse
Monoclonal
Liquid

**Description** 

Anti-PIM1 Rabbit Monoclonal Antibody . Tested in WB, IHC, ICC/IF applications. This antibody reacts with Human, Mouse.

## **Anti-PIM1 Rabbit Monoclonal Antibody - Additional Information**

**Gene ID 5292** 

**Other Names** 

Serine/threonine-protein kinase pim-1, 2.7.11.1, PIM1

Calculated MW 45412 MW KDa

**Application Details** 

WB 1:5000-1:10000<br>IHC 1:50-1:200<br>ICC/IF 1:50-1:200

**Subcellular Localization** 

Isoform 2: Cytoplasm. Nucleus.

**Tissue Specificity** 

Expressed primarily in cells of the hematopoietic and germline lineages. Isoform 1 and isoform 2 are both expressed in prostate cancer cell lines..

**Contents** 

Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol, 0.4-0.5mg/ml BSA.

**Immunogen** 

A synthesized peptide derived from human PIM1

**Purification** 

Affinity-chromatography

Storage

Store at -20°C for one year. For short term storage and frequent use, store at 4°C for up to one month. Avoid repeated



Tel: 858.875.1900 Fax: 858.875.1999

## freeze-thaw cycles.

### **Anti-PIM1 Rabbit Monoclonal Antibody - Protein Information**

#### Name PIM1

#### **Function**

Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis (PubMed:<a

href="http://www.uniprot.org/citations/15528381" target=" blank">15528381</a>, PubMed:<a href="http://www.uniprot.org/citations/1825810" target=" blank">1825810</a>, PubMed:<a href="http://www.uniprot.org/citations/31548394" target="\_blank">31548394</a>). Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3) (PubMed:<a href="http://www.uniprot.org/citations/18593906"

target=" blank">18593906</a>). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity (By similarity). The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis (By similarity). Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1 (By similarity). Phosphorylation of MAP3K5, another proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of INK and INK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis (PubMed:<a

href="http://www.uniprot.org/citations/19749799" target=" blank">19749799</a>). Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C (PubMed:<a href="http://www.uniprot.org/citations/16356754"

target=" blank">16356754</a>). Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability (PubMed: <a href="http://www.uniprot.org/citations/12431783"

target=" blank">12431783</a>). Promotes cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post-translational levels (PubMed:<a

href="http://www.uniprot.org/citations/18593906" target=" blank">18593906</a>). Phosphorylation of CDKN1B, induces 14-3-3 proteins binding, nuclear export and proteasome-dependent degradation (PubMed:<a

href="http://www.uniprot.org/citations/18593906" target=" blank">18593906</a>). May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3 (PubMed: <a href="http://www.uniprot.org/citations/10664448" target="\_blank">10664448</a>). Also acts as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis (By similarity). Acts as a positive regulator of mTORC1 signaling by mediating phosphorylation and inhibition of DEPDC5 component of the GATOR1 complex (PubMed: <a href="http://www.uniprot.org/citations/31548394" target="blank">31548394</a>). Acts as a negative regulator of innate immunity by mediating phosphorylation and inactivation of GBP1 in absence of infection: phosphorylation of GBP1 induces interaction with 14-3-3 protein sigma (SFN) and retention in the cytosol (PubMed:<a

href="http://www.uniprot.org/citations/37797010" target=" blank">37797010</a>). Also phosphorylates and activates the ATP-binding cassette transporter ABCG2, allowing resistance to drugs through their excretion from cells (PubMed:<a

href="http://www.uniprot.org/citations/18056989" target=" blank">18056989</a>). Promotes brown adipocyte differentiation (By similarity).

#### **Cellular Location**

[Isoform 1]: Cytoplasm. Nucleus.

#### **Tissue Location**

Expressed primarily in cells of the hematopoietic and germline lineages. Isoform 1 and isoform 2




are both expressed in prostate cancer cell lines.

## **Anti-PIM1 Rabbit Monoclonal Antibody - Protocols**


Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

# **Anti-PIM1 Rabbit Monoclonal Antibody - Images**




All lanes use the Antibody at 1:3K dilution for 1 hour at room temperature.




All lanes use the Antibody at 1:3K dilution for 1 hour at room temperature.





Western blot analysis of PIM1 expression in Jurkat cell lysate.



Immunohistochemical analysis of paraffin-embedded human prostate carcinoma, using PIM1 Antibody.